Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Mira Fitzek, Bianca Raffaelli & Uwe Reuter. (2022) Advances in pharmacotherapy for the prophylactic treatment of resistant and refractory migraine. Expert Opinion on Pharmacotherapy 23:10, pages 1143-1153.
Read now
Read now
Abimael González-Hernández, Miguel Condés-Lara, Enrique García-Boll & Carlos M. Villalón. (2021) An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. Expert Opinion on Drug Metabolism & Toxicology 17:2, pages 179-199.
Read now
Read now
Articles from other publishers (41)
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, Victoria Ruschil, Till Sprenger, David Lewis, Katharina Kamm, Tobias Freilinger, Lars Neeb, Volker Malzacher, Uwe Meier, Klaus Gehring, Torsten Kraya, Thomas Dresler, Christoph J. Schankin, Andreas R. Gantenbein, Gregor Brössner, Karin Zebenholzer, Hans-Christoph Diener, Charly Gaul & Tim P. Jürgens. (2022) Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen MigräneprophylaxeConsensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis. Der Nervenarzt 94:4, pages 306-317.
Crossref
Crossref
Lucas Hendrik Overeem, Kristin Sophie Lange, Mira Pauline Fitzek, Anke Siebert, Maureen Steinicke, Paul Triller, Ja Bin Hong, Uwe Reuter & Bianca Raffaelli. (2023) Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study. Frontiers in Neurology 14.
Crossref
Crossref
Bianca Raffaelli, Mira Fitzek, Lucas H. Overeem, Elisabeth Storch, Maria Terhart & Uwe Reuter. (2023) Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. The Journal of Headache and Pain 24:1.
Crossref
Crossref
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, Victoria Ruschil, Till Sprenger, David Lewis, Katharina Kamm, Tobias Freilinger, Lars Neeb, Volker Malzacher, Uwe Meier, Klaus Gehring, Torsten Kraya, Thomas Dresler, Christoph J. Schankin, Andreas R. Gantenbein, Gregor Brössner, Karin Zebenholzer, Hans-Christoph Diener, Charly Gaul & Tim P. Jürgens. (2022) Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen MigräneprophylaxeConsensus statement of the migraine and headache societies (DMKG, ÖKSG, and SKG) on the duration of pharmacological migraine prophylaxis. Der Schmerz 37:1, pages 5-16.
Crossref
Crossref
A. R. Sirazutdinova, A. A. Zvegintseva & M. L. Maksimov. (2023) Pharmacotherapy approaches to migraine prevention and treatment. Glavvrač (Chief Medical Officer):2, pages 28-41.
Crossref
Crossref
Beate Bittner. (2023) Customer-centric product presentations for monoclonal antibodies. AAPS Open 9:1.
Crossref
Crossref
Bianca Raffaelli, Maria Terhart, Mira Pauline Fitzek, Kristin Sophie Lange, Jasper Mecklenburg, Lucas Hendrik Overeem, Anke Siebert, Elisabeth Storch & Uwe Reuter. (2023) Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies. Pharmaceutics 15:1, pages 293.
Crossref
Crossref
Linda Sangalli & Stefania Brazzoli. (2023) Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments—New Therapeutic Technologies for Migraine. Future Pharmacology 3:1, pages 117-131.
Crossref
Crossref
E.A. Tkachenko, R.A. Elkanov, A.I. Raevskaya, I.A. Vyshlova & S.M. Karpov. (2023) Monoclonal antibodies to calcitonin gene-related peptide receptor for episodic migraine on the example of erenumab. Russian Journal of Pain 21:1, pages 73.
Crossref
Crossref
Ramesh Boinpally, Marleen Depré, Griet Van Lancker, Marissa F Dockendorf, Phung Bondiskey, Jean-Francois Denef, Tom Reynders, Catherine Zhou Matthews, K Chris Min, Jialin Xu, Joel M Trugman & Jan de Hoon. (2023) Pharmacokinetic and pharmacodynamic assessments of atogepant in healthy male adults: Results from phase 1 studies. Cephalalgia Reports 6.
Crossref
Crossref
Xing Wang, Dingke Wen, Qiang He, Chao You & Lu Ma. (2022) Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. The Journal of Headache and Pain 23:1.
Crossref
Crossref
Bianca Raffaelli, Maria Terhart, Jasper Mecklenburg, Lars Neeb, Lucas Hendrik Overeem, Anke Siebert, Maureen Steinicke & Uwe Reuter. (2022) Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. The Journal of Headache and Pain 23:1.
Crossref
Crossref
Amnon A. Berger, Joseph Keefe, Cain W. Stark, Matthew Moore, Giovanni F. Ramírez, Julia R. Cucarola, Andrew H. Han, Alan D. Kaye & Latha Ganti. (2022) Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults. Health Psychology Research 10:5.
Crossref
Crossref
Yusak Mangara Tua Siahaan, Vinson Hartoyo & Timotius Ivan Hariyanto. (2022) Efficacy and safety of eptinezumab as preventive treatment for episodic/chronic migraine: A systematic review and meta‐analysis. Clinical and Experimental Pharmacology and Physiology 49:11, pages 1156-1168.
Crossref
Crossref
Guy Boudreau, Ian Finkelstein, Corrie Graboski, May Ong, Suzanne Christie, Katherine Sommer, Meetu Bhogal, Goran Davidovic & Werner J. Becker. (2021) OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 49:4, pages 540-552.
Crossref
Crossref
Nazir Noor, Alexis Angelette, Abby Lawson, Anjana Patel, Ivan Urits, Omar Viswanath, Cyrus Yazdi & Alan D. Kaye. (2022) A Comprehensive Review of Zavegepant as Abortive Treatment for Migraine. Health Psychology Research 10:3.
Crossref
Crossref
Mária Dux, Birgit Vogler, Annette Kuhn, Kimberly D. Mackenzie, Jennifer Stratton & Karl Messlinger. (2022) The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow. Cells 11:11, pages 1768.
Crossref
Crossref
Caio Vinicius de Meira Grava Simioni. (2022) Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?. Arquivos de Neuro-Psiquiatria 80:5 suppl 1, pages 214-217.
Crossref
Crossref
Lucas Hendrik Overeem, Andreas Peikert, Maxi Dana Hofacker, Katharina Kamm, Ruth Ruscheweyh, Astrid Gendolla, Bianca Raffaelli, Uwe Reuter & Lars Neeb. (2021) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia 42:4-5, pages 291-301.
Crossref
Crossref
Bianca Raffaelli, Maria Terhart, Lucas Hendrik Overeem, Jasper Mecklenburg, Lars Neeb, Maureen Steinicke & Uwe Reuter. (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia 42:4-5, pages 326-334.
Crossref
Crossref
Linda Al-HassanyTessa de VriesJohannes A CarpayAntoinette MaassenVanDenBrink. (2021) Could erectile dysfunction be a side effect of CGRP inhibition? A case report. Cephalalgia 42:3, pages 257-261.
Crossref
Crossref
Kevin Ita & Monica Ukaoma. (2022) Progress in the transdermal delivery of antimigraine drugs. Journal of Drug Delivery Science and Technology 68, pages 103064.
Crossref
Crossref
Kyle W. Anderson, Christina Bergonzo, Kerry Scott, Ioannis L. Karageorgos, Elyssia S. Gallagher, Venkata S. Tayi, Michael Butler & Jeffrey W. Hudgens. (2022) HDX-MS and MD Simulations Provide Evidence for Stabilization of the IgG1—FcγRIa (CD64a) Immune Complex Through Intermolecular Glycoprotein Bonds. Journal of Molecular Biology 434:2, pages 167391.
Crossref
Crossref
Paolo Martelletti. 2022. Migraine in Medicine. Migraine in Medicine
1
209
.
Maria Terhart, Jasper Mecklenburg, Lars Neeb, Lucas Hendrik Overeem, Anke Siebert, Maureen Steinicke, Bianca Raffaelli & Uwe Reuter. (2021) Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(−receptor) antibodies. The Journal of Headache and Pain 22:1.
Crossref
Crossref
Simona Sacco, Christian Lampl, Antoinette Maassen van den Brink, Valeria Caponnetto, Mark Braschinsky, Anne Ducros, Patrick Little, Patricia Pozo-Rosich, Uwe Reuter, Elena Ruiz de la Torre, Margarita Sanchez Del Rio, Alexandra J. Sinclair, Paolo Martelletti & Zaza Katsarava. (2021) Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. The Journal of Headache and Pain 22:1.
Crossref
Crossref
Uwe Reuter, Christian Lucas, David Dolezil, Austin L. Hand, Martha D. Port, Russell M. Nichols, Chad Stroud, Antje Tockhorn-Heidenreich & Holland C. Detke. (2021) Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. Advances in Therapy 38:11, pages 5465-5483.
Crossref
Crossref
K.N. Westlund, M.A. Montera, A.E. Goins, S.R.A. Alles, M. Afaghpour-Becklund, R. Bartel, R. Durvasula & A. Kunamneni. (2021) Single-chain Fragment variable antibody targeting cholecystokinin-B receptor for pain reduction. Neurobiology of Pain 10, pages 100067.
Crossref
Crossref
Lucas Hendrik Overeem, Bianca Raffaelli, Jasper Mecklenburg, Tim Kelderman, Lars Neeb & Uwe Reuter. (2021) Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis. CNS Drugs 35:8, pages 805-820.
Crossref
Crossref
Eleonora De Matteis, Giannapia Affaitati, Ilaria Frattale, Valeria Caponnetto, Francesca Pistoia, Maria Adele Giamberardino, Simona Sacco & Raffaele Ornello. (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurological Sciences 42:8, pages 3297-3303.
Crossref
Crossref
Xiuyuan Zhao, Xiaolin Xu & Qingyun Li. (2020) Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis. Journal of Neurology 268:7, pages 2364-2376.
Crossref
Crossref
Kyle W. Anderson, Kerry Scott, Ioannis L. Karageorgos, Elyssia S. Gallagher, Tayi Venkata S., Michael Butler & Jeffrey W. Hudgens. (2021) Dataset from HDX-MS Studies of IgG1 Glycoforms and Their Interactions
with the FcγRIa (CD64) Receptor. Journal of Research of the National Institute of Standards and Technology 126.
Crossref
Crossref
Bixi Gao, Qiran Lu, Rong Wan, Zilan Wang, Yanbo Yang, Zhouqing Chen & Zhong Wang. (2020) Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials. Naunyn-Schmiedeberg's Archives of Pharmacology 394:4, pages 819-828.
Crossref
Crossref
Xing Wang, Yuqi Chen, Jinlei Song & Chao You. (2021) Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. Frontiers in Pharmacology 12.
Crossref
Crossref
Ruth Ruscheweyh & Jan Hoffmann. (2021) Neues in der Migränetherapie. Nervenheilkunde 40:03, pages 140-148.
Crossref
Crossref
Danuta Szkutnik-Fiedler. (2020) Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics 12:12, pages 1180.
Crossref
Crossref
Bianca Raffaelli. (2020) Patienten mit therapieresistenter chronischer Migräne im Praxisalltag. Schmerzmedizin 36:5, pages 37-39.
Crossref
Crossref
Erika Ivanna Araya, Joelle de Melo Turnes, Amanda Ribeiro Barroso & Juliana Geremias Chichorro. (2019) Contribution of intraganglionic CGRP to migraine-like responses in male and female rats. Cephalalgia 40:7, pages 689-700.
Crossref
Crossref
Ivan Urits, Gavin Clark, Daniel An, Bredan Wesp, Rebecca Zhou, Ariunzaya Amgalan, Amnon A. Berger, Hisham Kassem, Anh L. Ngo, Alan D. Kaye, Rachel J. Kaye, Elyse M. Cornett & Omar Viswanath. (2020) An Evidence-Based Review of Fremanezumab for the Treatment of Migraine. Pain and Therapy 9:1, pages 195-215.
Crossref
Crossref
Bixi Gao, Nan Sun, Yanbo Yang, Yue Sun, Mingjia Chen, Zhouqing Chen & Zhong Wang. (2020) Safety and Efficacy of Fremanezumab for the Prevention of Migraine: A Meta-Analysis From Randomized Controlled Trials. Frontiers in Neurology 11.
Crossref
Crossref
Nicolas Vandenbussche, Koen Paemeleire & Zaza Katsarava. (2020) The Many Faces of Medication‐Overuse Headache in Clinical Practice. Headache: The Journal of Head and Face Pain 60:5, pages 1021-1036.
Crossref
Crossref